These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. A semiparametric model for regression analysis of interval-censored failure time data. Finkelstein DM; Wolfe RA Biometrics; 1985 Dec; 41(4):933-45. PubMed ID: 3830259 [TBL] [Abstract][Full Text] [Related]
26. The NCI All Ireland Cancer Conference. Johnston PG; Daly PA; Liu E Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862 [TBL] [Abstract][Full Text] [Related]
27. MRI for development of disease-modifying osteoarthritis drugs. Burstein D NMR Biomed; 2006 Oct; 19(6):669-80. PubMed ID: 16986116 [TBL] [Abstract][Full Text] [Related]
28. Contraceptive development and clinical trials. Fraser IS Clin Reprod Fertil; 1986 Feb; 4(1):75-85. PubMed ID: 3708511 [TBL] [Abstract][Full Text] [Related]
29. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. Driessen RJ; Boezeman JB; van de Kerkhof PC; de Jong EM Br J Dermatol; 2009 Mar; 160(3):670-5. PubMed ID: 19210502 [TBL] [Abstract][Full Text] [Related]
30. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems. Glasser SP; Salas M; Delzell E J Clin Pharmacol; 2007 Sep; 47(9):1074-86. PubMed ID: 17766697 [TBL] [Abstract][Full Text] [Related]
31. Postmarketing studies of drug efficacy: when must they be randomized? Strom BL; Miettinen OS; Melmon KL Clin Pharmacol Ther; 1983 Jul; 34(1):1-7. PubMed ID: 6861430 [No Abstract] [Full Text] [Related]
32. [The limits of controlled clinical studies: the case of rheumatology]. Portioli I Ann Ital Med Int; 2000; 15(1):39-46. PubMed ID: 10842890 [TBL] [Abstract][Full Text] [Related]
33. The role of databases in drug postmarketing surveillance. Rodriguez EM; Staffa JA; Graham DJ Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586 [TBL] [Abstract][Full Text] [Related]
34. [Clinical trials with drugs: the influence of the authorization process]. Carcas AJ; Serrano MA; Avendaño C; Galende I; Tristán C; García-Alonso F Med Clin (Barc); 1995 May; 104(18):683-8. PubMed ID: 7769877 [TBL] [Abstract][Full Text] [Related]
35. Procedures and methods of benefit assessments for medicines in Germany. Bekkering GE; Kleijnen J Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905 [TBL] [Abstract][Full Text] [Related]
36. The scope and requirements related to preclinical and clinical studies of a new medicinal product, including biotechnological and biosimilar products. Brodniewicz-Proba T Acta Pol Pharm; 2008; 65(6):641-5. PubMed ID: 19172845 [TBL] [Abstract][Full Text] [Related]
37. Postmarketing surveillance. Oleen MA Can J Hosp Pharm; 1987 Oct; 40(5):171-2, 179-80. PubMed ID: 10284449 [TBL] [Abstract][Full Text] [Related]
38. [How to assess new medical devices]. Bernard A; Vicaut E J Chir (Paris); 2009 Apr; 146(2):129-35. PubMed ID: 19524920 [TBL] [Abstract][Full Text] [Related]
39. Confidentiality laws and secrecy in medical research: improving public access to data on drug safety. Kesselheim AS; Mello MM Health Aff (Millwood); 2007; 26(2):483-91. PubMed ID: 17339677 [TBL] [Abstract][Full Text] [Related]
40. FastSize Medical Extender for the treatment of Peyronie's disease. Levine LA; Newell MM Expert Rev Med Devices; 2008 May; 5(3):305-10. PubMed ID: 18452379 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]